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Each year there are two international scientific 
meetings devoted entirely to cystic fibrosis (CF); one 
North American, and one European. The Pro- 
ceedings of The Annual North American Conference 
are published as a supplement to Pediatric Pulmon- 
ology which contains short extended abstracts of 
Symposium presentations, as well as all the accepted 
abstracts for poster presentations. The European 
counterpart often has the same format, but it is 
usually available to participants only. However, at 
the 18th European CF Conference in Madrid, May 
1993, the local scientific and organizing committee 
asked a number of active participants, including all 
invited speakers, to prepare full papers on their 
presentations. This has resulted in this book which 
contains 52 articles grouped under the headings: 
Molecular Pathogenesis and Ion Transport; Genet- 
ics; Microbiology; Pseudomonas cepacia (recently 
re-named Burkholderi cepacia); Antibiotic Therapy; 
Immunology; Up-date on Therapies; Pulmonology; 
Nutrition and Gastroenterology; Reproduction; and 
Epidemiology. The latter includes some presentations 
not easily included under the other headings. 
The large majority of papers deal with clinical 
aspects of the disease which reflects the composition 
of active participants, which, by tradition, is made up 
primarily of clinicians and of scientists working 
within the fields of clinical immunology and clinical 
microbiology. It is well known that the disclosure of 
the molecular defect(s) in CF has recruited an 
increasing number of scientists working within 
molecular genetics and cell physiology into CF 
research, but the attendance of active participants 
from basic sciences is much more pronounced at the 
North American than at the European CF Confer- 
ences. In this book, only the first six contributions 
deal with these aspects which, however, include excel- 
lent up-dates on the progress towards gene therapy in 
morbidity and mortality in CF, so naturally many 
contributions (25) deal with these aspects. A number 
of these papers focus on antibiotic treatment, includ- 
ing new antimicrobial agents and different routes of 
administration. There are excellent review articles on 
the immunologic and inflammatory host reactions, 
which ultimately lead to respiratory insufficiency. 
These important aspects provide the basis for new 
approaches to treatment, using anti-inflammatory 
drugs, several of which have now been explored in 
clinical practice. An important contribution deals 
with the early clinical studies on the effects of inhaled 
human recombinant DNase, a novel treatment 
approach, which by now is in use world-wide in 
clinical practice. Others up-date the experience on 
double-lung and heart-lung transplantation for end- 
stage lung disease, written by experienced experts. 
The remaining papers deal, amongst others, with 
various aspects of nutrition, and with the liver disease 
in CF, including clinical experience with ursodeoxy- 
cholic acid treatment. The improved survival in CF 
has resulted in a growing number of child-bearing CF 
patients presenting a whole new set of problems for 
the clinician who already has to deal with this 
multi-organ, multi-facetted disease. 
The proceedings of the Annual North American 
and European CF Conferences, as well as of the 
International CF Conferences which take place less 
often, are indispensable in CF centres and this book, 
with its many carefully prepared papers and with a 
large number of excellent illustrations, is certainly of 
an improved standard compared with the usual 
European proceedings. It should thereby reach a 
wider audience and it will undoubtedly prove more 
valuable than the usual Conference proceedings as an 
easy source of specialized knowledge in day-to-day 
work in CF centres around the world. 
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disorders. The anti-asthma drugs have a choice 
position, but chemotherapy for lung cancers and 
antibiotics are also studied. As the book has been 
written from a pharmacological point of view, the 
treatment of asthma (for example) is analytical; there 
is no synthesis and no strategy (it is not the aim of the 
book). 
One of the best qualities of Drugs and the Jung 
is the large quantity of references: 651 for gluco- 
corticosteroids. They are analysed and discussed in 
depth. 
In the second section (seven chapters out of 16), 
drugs which are under investigation are discussed. 
The so-called ‘anti-leukotrienes’ (antagonists and 
inhibitors) have only a brief mention. Zileuton is 
close to being marketed and is more promising than 
PAF-antagonists (at least in the very near future). 
There is no mention of gene therapy. 
This book is well-documented and should be of 
great interest to clinicians and students. 
/?-agonists are the subject of the first chapter 
(glucocorticosteroids could have been another good 
choice to emphasize its importance). The mechanism 
of action is briefly summarized and it is quite surpris- 
ing to note that the effects of &agonists on inflam- 
matory cells have been discussed in depth, as 
compared to their effects on smooth muscles. The 
regular use of &agonists in asthmatics has been 
clearly discussed: the conclusion is that this subject is 
highly controversial but the author suggests their use 
on a pm basis. However, the new long-acting 
&agonists (by inhalation and per OS) could modify 
the strategy and will have to be evaluated completely. 
Anti-cholinergic therapy has been clearly reviewed 
by Professor P. Barnes. The understanding of the 
receptor subtype is very important: hence six 
explanatory figure in this short chapter. 
Xanthines are the object of some controversy and I 
would like to add my contribution: the authors 
forgot to mention that Laennec also recommended to 
his patients to drink coffee! More seriously, it is very 
surprising that the mechanism of action is so badly 
understood. The authors performed several works 
and suggest that theophylline could have anti- 
inflammatory properties. I would also like to add my 
personal contribution, based on my daily clinical 
expertise; most of the asthmatics who tolerate theo- 
phylline are very compliant to this drug and their 
asthma worsens if they stop (for any reason). 
The chapter on glucocorticosteroids is probably 
the most interesting, as well as the longest (more than 
100 pages). All the aspects of these unique drugs have 
been developed in depth. The authors have been able 
to explain clearly the mechanisms of action from the 
DNA site to the patient..The treatment of asthma 
is discussed, as expected, but also the other lung 
disorders. 
Prophylactic anti-asthma drugs (cromoglycate and 
nedocromil) are the subject of a specific chapter, 
which also includes anti-histamines. These are clearly 
indicated in the treatment of rhinitis, and not in 
asthma. However, the improvement of the rhinitis 
could have some effect on the airways. This aspect 
could have been discussed. 
One chapter has been entitled ‘immunosuppressive 
agents’. In fact it should have been entitled ‘steroid 
sparing drugs’, because all these indications have 
been used with this objective and because the mech- 
anism of action is the subject of controversy. 
The chapter on chemotherapy in lung cancer 
aims to define the respective place of chemotherapy, 
radiation therapy, immunotherapy and surgery in the 
treatment of both small cell and non-small cell lung 
cancers. 
It is noteworthy that dealing with such an extensive 
topic in a very limited place is a real challenge. From 
this point of view, this is a good chapter. However, 
there are some weaknesses. It might be interesting to 
emphasize recent advances, such as: 
- Mixed small cell-non-small lung cancer; 
-Negative survival effect of slight dose reduction 
during the first cycle of SCLC chemotherapy; 
-Use of cytokines as maintenance therapy in 
responder SCLC patients (at least, to say that the 
studies are, at that point, negative); 
- Prognostic effect of combined chemotherapy- 
radiation therapy in limited small cell lung cancer; 
- Timing of radiation therapy in combined modality 
treatment; and 
- Recommendations on use of haematopoietic 
growth factor as adjunct to SCLC chemotherapy. 
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Biopsy interpretation of the Jung by Shimosato and 
Miller is a volume in the Biopsy Interpretation Series 
by Raven Press. It is a small book compared with 
several very extensive new additions of lung pathol- 
ogy books published within the last couple of years. 
But it is good! 
Part I (11 chapters) deals with infiltrative lung 
disease and Part II (14 chapters) with benign and 
malignant tumours (including those of pleura). 
